- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Schizophrenia
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1668KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 452KB)
Cariprazine – November 2020
Cariprazine: Capsule 1.5 mg, Capsule 3 mg, Capsule 4.5 mg, Capsule 6 mg; Reagila®
Last updated
5 March 2021